Fatty diacid comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
== Research == Ariely's research is in the area of consumer behavior, and he studies how people often make irrational decisions. Below are some common themes. Critique of classical economic assumptions and consumer behavior Ariely has challenged the assumptions of classical economics by showing that consumer valuations are influenced by arbitrary anchors and external cues. His research on the "Zero Price Effect" demonstrates how free products distort perceived value beyond rational cost-benefit logic. Dishonesty and ethics His studies have shown that people rationalize small acts of dishonesty to maintain a positive self-image, thus balancing moral integrity with personal gain. Emotional influence on economic decisions Ariely has examined how emotions like love or anger distort rational decision-making and self-control. His experiments have shown that emotional states can lead to riskier or less ethical economic choices. Workplace motivation Ariely's research found that meaning, recognition, and purpose drive productivity more than financial incentives. In studies conducted with Intel, he found that overreliance on monetary rewards can lead to reduced motivation in the long term.
In 1965, Chinese scientists first synthesized crystalline bovine insulin (Chinese: 人工合成结晶牛胰岛素), which was the first functional crystalline protein being fully synthesized in the world. Research on synthesizing bovine insulin started on 1958. Members in the research group were from the Chemistry Department of Beijing University (Chinese: 北京大学化学系), Shanghai Institute of Biochemistry, CAS (Chinese: 中科院上海生物化学研究所) and Shanghai Institute of Organic Chemistry, CAS (Chinese: 中科院上海有机化学研究所). Insulin is a protein (peptide) consisting of two chain, A and B. Chain A consists of 21 amino acid residues while chain consists of 30 amino acid residues. The main function of insulin is to regulate the concentrate of sugar in blood. Type 1 diabetes are caused by dysfunction on the synthesis or secretory of insulin while injecting insulin can treat type 1 diabetes. In 1979, Wang Yinglai, the project's lead scientist, nominated Niu Jingyi, a team member who had made significant contributions, for the Nobel Chemistry Prize, but the nomination was unsuccessful.
=== Peripheral === Thyroxine is believed to be a prohormone and a reservoir for the most active and main thyroid hormone, T3. T4 is converted as required in the tissues by iodothyronine deiodinase. Deficiency of deiodinase can mimic hypothyroidism due to iodine deficiency. T3 is more active than T4, though it is present in less quantity than T4.
== Veterinary use == Lidocaine is commonly used in veterinary medicine in both companion and production animals around the world and is listed as an essential veterinary medicine by the World Veterinary Association and also the World Small Animal Veterinary Association.[1] In veterinary medicine, it is commonly used as a local anaesthetic both as an injectable or topical product. It provides excellent local anaesthesia when given by local infiltration into a tissue or via specific nerve blocks. These are commonly applied to nerves of the head, limbs, thorax, and spine. It can also be used to treat ventricular arrhythmias when given intravenously. In most veterinary species, when given via injection, it has a rapid onset of action (2-10 minutes) with a duration of action of 30-60 minutes. In veterinary species, its metabolism is much the same as humans with rapid metabolism in the liver to the major metabolites MEGX (monoethylglycine xylidide) and GX (glycine xylidide) that retain partial activity against sodium channels. These compounds are further metabolized to monoethylglycine and xylidide, respectively. Toxicity in animals is similar to that seen in humans with both toxicity to the central nervous system (CNS) and cardiovascular system observed. General the CNS signs are seen first with agitation and muscle twitching seen before the cardiovascular signs of hypotension, myocardial depression, and arrhythmias. Further CNS depression will result from higher doses with seizures and convulsions and eventually apnea and death.
Sources: en.wikipedia.org
In petrol engines, instead, the vacuum is typically obtained as a side-effect of the operation of the engine and the flow restriction created by the throttle plate but may be also supplemented by an electrically operated vacuum pump to boost braking assistance or improve fuel consumption. This vacuum may then be used to power the following motor vehicle components: vacuum servo booster for the hydraulic brakes, motors that move dampers in the ventilation system, throttle driver in the cruise control servomechanism, door locks or trunk releases. In an aircraft, the vacuum source is often used to power gyroscopes in the various flight instruments. To prevent the complete loss of instrumentation in the event of an electrical failure, the instrument panel is deliberately designed with certain instruments powered by electricity and other instruments powered by the vacuum source. Depending on the application, some vacuum pumps may either be electrically driven (using electric current) or pneumatically driven (using air pressure), or powered and actuated by other means.
== Diagnosis == Acanthosis nigricans is typically diagnosed clinically based on its characteristic velvety hyperpigmentation and distribution. A skin biopsy is rarely needed but, when performed, shows hyperkeratosis, papillomatosis and mild basal hyperpigmentation. Evaluation aims to identify associated conditions. Investigations may include:
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Haunted Heat (HIGH) The contestant had one of the best dishes in the Haunted Heat. (IN) The contestant performed well enough to move on to the next week. ‡ The judges recognized this contestant for having the best dish in the Bake for Your Life challenge. (LOW) The contestant had one of the bottom dishes but was not eliminated. (OUT) The contestant was eliminated for worst dish.
Sources: en.wikipedia.org
=== Regulation by keap1/nrf2/are pathway === External (via chemicals) and internal (stress response or caloric restriction) induction of NQO1 is mediated solely through the Keap1/Nrf2/ARE. Keap1 acts as the sensor which loses its ability to target Nrf2 for degradation upon exposure to the inducers. Nrf2 is consequently stabilized and accumulated in the nucleus upon which it binds to the AREs and initiates expression of cytoprotective genes including NQO1.
=== Social sciences === Finance: a retirement fund will decay exponentially being subject to discrete payout amounts, usually monthly, and an input subject to a continuous interest rate. A differential equation dA/dt = input − output can be written and solved to find the time to reach any amount A, remaining in the fund. In simple glottochronology, the (debatable) assumption of a constant decay rate in languages allows one to estimate the age of single languages. (To compute the time of split between two languages requires additional assumptions, independent of exponential decay).
DHRs can also be determined for specific sites in a drug by 2H NMR, and has been used to distinguish between different synthetic methods for ibuprofen and naproxen in one study, and prozac and fluoxetine in another. These studies show that bulk DHR information for EA-IRMS, and site-specific DHRs from 2H NMR have great utility for pharmaceutical drug authenticity testing.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.